Related Experiment Videos

Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in

Y Kitamura1, P J Goodfellow, K Shimizu

  • 1Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.

Oncogene
|June 26, 1997
PubMed

Insights

New RET proto-oncogene mutations predispose to medullary thyroid carcinoma (MTC). Researchers identified three novel germ-line mutations in Japanese MTC patients, suggesting a genetic link to MTC development.

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Germ-line and somatic mutations in the RET proto-oncogene are linked to medullary thyroid carcinoma (MTC).
  • Most Multiple Endocrine Neoplasia type 2A (MEN2A) and Familial Medullary Thyroid Carcinoma (FMTC) patients have germ-line point mutations affecting cysteine residues.

Purpose of the Study:

  • To investigate RET proto-oncogene mutations in Japanese MTC patients.
  • To identify novel mutations predisposing to MTC.

Main Methods:

  • Sequencing of exons 10, 11, 13, 14, and 16 of the RET proto-oncogene.
  • Analysis of germ-line DNA from 33 unrelated Japanese MTC patients.

Main Results:

  • Germ-line mutations were identified in 11 out of 33 (33%) MTC patients.
  • Three novel RET mutations were discovered in exons 10 and 11: Cys620Gly, Cys630Ser, and Cys630Tyr.
  • These mutations were found in four unrelated patients without a documented family history of MTC.

Conclusions:

  • The newly identified RET mutations involve cysteine residues within a region associated with FMTC and MEN2A.
  • These novel RET alleles likely represent predisposing mutations for medullary thyroid carcinoma development.

Related Concept Videos